141 related articles for article (PubMed ID: 12684918)
21. Incidence, clinical presentation, and outcome of progressive multifocal leukoencephalopathy in HIV-infected patients during the highly active antiretroviral therapy era: a nationwide cohort study.
Engsig FN; Hansen AB; Omland LH; Kronborg G; Gerstoft J; Laursen AL; Pedersen C; Mogensen CB; Nielsen L; Obel N
J Infect Dis; 2009 Jan; 199(1):77-83. PubMed ID: 19007313
[TBL] [Abstract][Full Text] [Related]
22. Immune reconstitution after potent antiretroviral therapy in AIDS patients with progressive multifocal leukoencephalopathy.
D'Amico R; Sarkar S; Yusuff J; Azar E; Perlman DC
Scand J Infect Dis; 2007; 39(4):347-50. PubMed ID: 17454900
[TBL] [Abstract][Full Text] [Related]
23. Treatment interruption of highly active antiretroviral therapy in patients with nadir CD4 cell counts >200 cells/mm3.
Toulson AR; Harrigan R; Heath K; Yip B; Brumme ZL; Harris M; Hogg RS; Montaner JS
J Infect Dis; 2005 Nov; 192(10):1787-93. PubMed ID: 16235178
[TBL] [Abstract][Full Text] [Related]
24. New features of progressive multifocal leukoencephalopathy in the era of highly active antiretroviral therapy and natalizumab.
Lima MA; Koralnik IJ
J Neurovirol; 2005; 11 Suppl 3():52-7. PubMed ID: 16540456
[TBL] [Abstract][Full Text] [Related]
25. Prevalence, associated factors, and prognostic determinants of AIDS-related toxoplasmic encephalitis in the era of advanced highly active antiretroviral therapy.
Antinori A; Larussa D; Cingolani A; Lorenzini P; Bossolasco S; Finazzi MG; Bongiovanni M; Guaraldi G; Grisetti S; Vigo B; Gigli B; Mariano A; Dalle Nogare ER; De Marco M; Moretti F; Corsi P; Abrescia N; Rellecati P; Castagna A; Mussini C; Ammassari A; Cinque P; d'Arminio Monforte A;
Clin Infect Dis; 2004 Dec; 39(11):1681-91. PubMed ID: 15578371
[TBL] [Abstract][Full Text] [Related]
26. Effect of maintaining highly active antiretroviral therapy on AIDS events among patients with late-stage HIV infection and inadequate response to therapy.
Gandhi T; Wei W; Amin K; Kazanjian P
Clin Infect Dis; 2006 Mar; 42(6):878-84. PubMed ID: 16477568
[TBL] [Abstract][Full Text] [Related]
27. Macrophage chemoattractant protein-1 levels in cerebrospinal fluid correlate with containment of JC virus and prognosis of acquired immunodeficiency syndrome--associated progressive multifocal leukoencephalopathy.
Marzocchetti A; Cingolani A; Giambenedetto SD; Ammassari A; Giancola ML; Cauda R; Antinori A; Luca AD
J Neurovirol; 2005 Apr; 11(2):219-24. PubMed ID: 16036800
[TBL] [Abstract][Full Text] [Related]
28. [Progressive multifocal leukoencephalopathy--epidemiology, clinical pictures, diagnosis and therapy].
Kishida S
Brain Nerve; 2007 Feb; 59(2):125-37. PubMed ID: 17380777
[TBL] [Abstract][Full Text] [Related]
29. Predictors of clinical progression among HIV-1-positive patients starting HAART with CD4+ T-cell counts > or =200 cells/mm3.
Lapadula G; Torti C; Maggiolo F; Casari S; Suter F; Minoli L; Pezzoli C; Di Pietro M; Migliorino G; Ouiros-Roldan E; Ladisa N; Sighinolfi L; Costarelli S; Carosi G;
Antivir Ther; 2007; 12(6):941-7. PubMed ID: 17926648
[TBL] [Abstract][Full Text] [Related]
30. When to begin highly active antiretroviral therapy? Evidence supporting initiation of therapy at CD4+ lymphocyte counts <350 cells/microL.
Kaplan JE; Hanson DL; Cohn DL; Karon J; Buskin S; Thompson M; Fleming P; Dworkin MS;
Clin Infect Dis; 2003 Oct; 37(7):951-8. PubMed ID: 13130408
[TBL] [Abstract][Full Text] [Related]
31. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.
McDermott AY; Terrin N; Wanke C; Skinner S; Tchetgen E; Shevitz AH
Clin Infect Dis; 2005 Dec; 41(11):1662-70. PubMed ID: 16267741
[TBL] [Abstract][Full Text] [Related]
32. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.
Kilaru KR; Kumar A; Sippy N; Carter AO; Roach TC
HIV Med; 2006 Mar; 7(2):99-104. PubMed ID: 16420254
[TBL] [Abstract][Full Text] [Related]
33. Depression and clinical progression in HIV-infected drug users treated with highly active antiretroviral therapy.
Bouhnik AD; Préau M; Vincent E; Carrieri MP; Gallais H; Lepeu G; Gastaut JA; Moatti JP; Spire B;
Antivir Ther; 2005; 10(1):53-61. PubMed ID: 15751763
[TBL] [Abstract][Full Text] [Related]
34. Factors influencing increases in CD4 cell counts of HIV-positive persons receiving long-term highly active antiretroviral therapy.
Smith CJ; Sabin CA; Youle MS; Kinloch-de Loes S; Lampe FC; Madge S; Cropley I; Johnson MA; Phillips AN
J Infect Dis; 2004 Nov; 190(10):1860-8. PubMed ID: 15499544
[TBL] [Abstract][Full Text] [Related]
35. Impact of baseline viral load and adherence on survival of HIV-infected adults with baseline CD4 cell counts > or = 200 cells/microl.
Wood E; Hogg RS; Yip B; Moore D; Harrigan PR; Montaner JS
AIDS; 2006 May; 20(8):1117-23. PubMed ID: 16691062
[TBL] [Abstract][Full Text] [Related]
36. A prospective study demonstrates an association between JC virus-specific cytotoxic T lymphocytes and the early control of progressive multifocal leukoencephalopathy.
Du Pasquier RA; Kuroda MJ; Zheng Y; Jean-Jacques J; Letvin NL; Koralnik IJ
Brain; 2004 Sep; 127(Pt 9):1970-8. PubMed ID: 15215217
[TBL] [Abstract][Full Text] [Related]
37. Response to highly active antiretroviral therapy among severely immuno-compromised HIV-infected patients in Cambodia.
Madec Y; Laureillard D; Pinoges L; Fernandez M; Prak N; Ngeth C; Moeung S; Song S; Balkan S; Ferradini L; Quillet C; Fontanet A
AIDS; 2007 Jan; 21(3):351-9. PubMed ID: 17255742
[TBL] [Abstract][Full Text] [Related]
38. Prognostic value of plasma HIV RNA among highly active antiretroviral therapy users.
Tarwater PM; Gallant JE; Mellors JW; Gore ME; Phair JP; Detels R; Margolick JB; Muñoz A
AIDS; 2004 Dec; 18(18):2419-23. PubMed ID: 15622318
[TBL] [Abstract][Full Text] [Related]
39. Setting a minimum threshold CD4 count for initiation of highly active antiretroviral therapy in HIV-infected patients.
Ho C; Lee S; Wong Kh; Cheng L; Lam M
HIV Med; 2007 Apr; 8(3):181-5. PubMed ID: 17461862
[TBL] [Abstract][Full Text] [Related]
40. Predicting the evolution of Kaposi sarcoma, in the highly active antiretroviral therapy era.
El Amari EB; Toutous-Trellu L; Gayet-Ageron A; Baumann M; Cathomas G; Steffen I; Erb P; Mueller NJ; Furrer H; Cavassini M; Vernazza P; Hirsch HH; Bernasconi E; Hirschel B;
AIDS; 2008 May; 22(9):1019-28. PubMed ID: 18520345
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
